A 2018 review of 16 studies of cannabis-centered medicines for neuropathic pain, most of which analyzed a cannabinoid preparing identified as nabiximols (model identify Sativex; a mouth spray containing the two THC and CBD that is authorized in some nations but not in the United States), observe